MicroRNAs: Commercial Products on the Horizon

Table of Contents

Chapter 1 INTRODUCTION

• 1.1. State of the Science
• 1.2. Why Did MicroRNAs Escape Notice?
• 1.3. The Discovery of MicroRNAs
  • Enter RNA Interference
  • The Initial Papers
  • Defining and Describing MicroRNAs
    • Criteria
    • Genomic Addresses
    • Abundance and Diversity
• 1.4. Mechanisms and Targets
  • MicroRNAs in Plants and Animals
  • From Precursor to Mature MicroRNA
  • Targets
• 1.5. MicroRNA Sequence Variation
• 1.6. Evolutionary Significance
• 1.7. Analysis

Chapter 2 THE TECHNOLOGICAL LANDSCAPE

• 2.1. Collecting and Profiling MicroRNAs
  • The Workflow: Isolate, Enrich, Detect, Quantify, and Analyze
  • Arrays and Assays
  • Customized Microarrays
• 2.2. Inhibiting MicroRNAs
  • Locked Nucleic Acid Modified Antisense Oligonucleotides
  • Morpholinos
  • Antagomirs
  • MicroRNA Sponges
• 2.3. Databases and Computational Tools
  • MiRBase
  • Computational Tools (In Silico Predictions)

Chapter 3 CLINICAL APPLICATIONS

• 3.1. Oncology
  • Onco-miRs and Tumor-Suppressor MicroRNAs
  • let-7 Led the Way
  • Further Evidence Linking MicroRNAs to Cancer
  • Clinical Applications of MicroRNAs in Cancer
    • Diagnosis
    • Therapeutics
• 3.2. Infectious Disease
  • Cytomegalovirus (CMV)
  • Human Immunodeficiency Virus (HIV)
• 3.3. Neurological Disease
• 3.4. Cardiovascular Disease

Chapter 4 BASIC RESEARCH

• 4.1. Differentiation and Development
  • MicroRNA Control in Embryos
  • Role of MicroRNAs in Aging
• 4.2. Evolution

Chapter 5 COMMERCIAL OUTLOOK

• 5.1. Promises and Caveats
• 5.2. Commercialization
  • Companies Devoted Exclusively to MicroRNAs
  • RNAi Companies Developing MicroRNAs
  • Spinouts from 1 or More Companies
  • Big Pharma
  • Traditional Suppliers of Reagents and Kits
• 5.3. Patent and Intellectual Property Issues
  • Recent MicroRNA Patents
  • The RNAi Legacy
• 5.4. The Future

Chapter 6 EXPERT INTERVIEWS

• Christoper Adams, PhD, Research Area Manager, Research & Development/Epigenetics, Invitrogen, Carlsbad, CA
• Dalia Cohen, PhD, Executive Vice President, Head of Global Research and Development, Rosetta Genomics, Rehovot, Israel and North Brunswick, NJ
• Iain Russell, PhD, Product Manager, TaqMan MicroRNA Assays, Applied Biosystems, Foster City, CA
• Frank Slack, PhD, Associate Professor of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT
• Phillip D. Zamore, PhD, Gretchen Stone Cook Professor of Biomedical Sciences, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA

Chapter 7 SELECTED COMPANY PROFILES

• Agilent Technologies
• Asuragen
• Cepheid and Actigenics-Cepheid
• Dharmacon Products (part of Thermo Fisher Scientific)
• Exiqon
• Invitrogen
• Luminex
• QIAGEN
• Regulus Therapeutics
• Rosetta Genomics
• Santaris Pharma

Appendix

• INSIGHT PHARMA REPORTS MicroRNA SURVEY-DECEMBER 2007

Glossary

• References
• Company Index with Web Addresses